Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 2,413 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Occlusive Vascular Disease Clear all
Completed Phase 2 Interventional Results available

NeuroCognition After Carotid Recanalization

NCT04219774
View directory record Official record
Conditions
Cognition Disorder, Stroke, Occlusion Carotid
Interventions
Endovascular intervention, Aspirin and Clopidogrel (maximal medical Therapy)
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 15, 2026, 10:59 AM EDT
Active, not recruiting Not applicable Interventional Results available

LIFE-BTK PK Sub-study

NCT05208905
View directory record Official record
Conditions
Critical Limb Ischemia (CLI)
Interventions
Esprit BTK Device
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Jacksonville, Florida • South Dartmouth, Massachusetts • Bartlesville, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 15, 2026, 10:59 AM EDT
Completed No phase listed Observational

Neurological Outcome With Carotid Artery Stenting

NCT00597974
View directory record Official record
Conditions
Carotid Artery Disease, Carotid Artery Stenosis, Stroke, Transient Ischemic Attack
Interventions
Angioplasty, Stent, Neurological and neuropsychological evaluations, Angiography
Procedure · Device · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 15, 2026, 10:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Aspirin and Thienopyridine Resistance in Peripheral Arterial Disease

NCT03174990
View directory record Official record
Conditions
Peripheral Arterial Disease, Clopidogrel, Poor Metabolism of
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 15, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET

NCT00733460
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
BFPET
Drug
Lead sponsor
Fluoropharma, Inc.
Industry
Eligibility
20 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 15, 2026, 10:59 AM EDT
Completed Phase 1 Interventional

Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension

NCT00023296
View directory record Official record
Conditions
Sickle Cell Anemia, Pulmonary Hypertension
Interventions
Nitric Oxide, INO Pulse - NO Delivery System
Drug · Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 15, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion

NCT01198327
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
ranibizumab, Peripheral Laser
Drug · Other
Lead sponsor
Peter A Campochiaro, MD
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
Beverly Hills, California • Sacremento, California • Augusta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 15, 2026, 10:59 AM EDT
Terminated Phase 3 Interventional

Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

NCT00060996
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain
Interventions
Remodulin® (treprostinil sodium) Injection
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
7
States / cities
Tampa, Florida • Worcester, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 15, 2026, 10:59 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Needle Free Assessment of Myocardial Oxygenation in Healthy Subjects

NCT06000540
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
RespirAct
Device
Lead sponsor
Indiana University
Other
Eligibility
45 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 15, 2026, 10:59 AM EDT
Completed Not applicable Interventional Results available

Transitional Rehabilitation in CABG Patients

NCT03892460
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Bypass Graft Surgery
Interventions
neuromuscular electrical stimulation
Device
Lead sponsor
University of Vermont
Other
Eligibility
50 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 15, 2026, 10:59 AM EDT
Completed No phase listed Observational Results available

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol

NCT05635370
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Pentoxifylline, Cilostazol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
10,398 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 15, 2026, 10:59 AM EDT
Recruiting Phase 3 Interventional

Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

NCT07318610
View directory record Official record
Conditions
Peripheral Artery Disease (PAD)
Interventions
REGN7508, REGN9933, Placebo, Rivaroxaban
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
21
States / cities
Alexander City, Alabama • Avondale, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 15, 2026, 10:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thrombin Regulated Platelet Activation

NCT00855296
View directory record Official record
Conditions
Coronary Artery Disease, Acute Coronary Syndrome
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 15, 2026, 10:59 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study

NCT01522742
View directory record Official record
Conditions
Psoriasis
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 15, 2026, 10:59 AM EDT
Completed Not applicable Interventional

Urolithin A Supplementation in Middle-aged Adults With Obesity

NCT05921266
View directory record Official record
Conditions
Obesity, Vascular Dementia, Cognitive Impairment
Interventions
Urolithin A, Placebo
Dietary Supplement · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
40 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 15, 2026, 10:59 AM EDT
Not listed Not applicable Interventional

Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion

NCT01581151
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Dexamethasone intravitreal implant, Monthly Ranibizumab
Drug
Lead sponsor
Brian Burke, MPH
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 15, 2026, 10:59 AM EDT
Recruiting Not applicable Interventional

Pulsed Electromagnetic Field Treatment With Dementia Patients

NCT06862557
View directory record Official record
Conditions
Alzheimer's Disease, Lewy Body Dementia, Vascular Dementia
Interventions
ECHS AD Device
Device
Lead sponsor
Herrick Medical LLC
Industry
Eligibility
50 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 15, 2026, 10:59 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease 007

NCT00595673
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PB127 for injectable suspension
Drug
Lead sponsor
Point Biomedical
Industry
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
19
States / cities
Scottsdale, Arizona • San Francisco, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2008 · Synced Oct 15, 2026, 10:59 AM EDT
Terminated No phase listed Observational

Cardiac Cath Lab Staff Radiation Exposure

NCT03959072
View directory record Official record
Conditions
Coronary Artery Disease, Chronic Total Occlusion of Coronary Artery, Percutaneous Coronary Intervention
Interventions
Robotic CTO PCI, Conventional (Manual) CTO PCI
Device · Procedure
Lead sponsor
Siemens Healthineers Endovascular Robotics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Timeline
2019 – 2021
U.S. locations
3
States / cities
Kansas City, Missouri • York, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 15, 2026, 10:59 AM EDT
Completed Phase 3 Interventional

Rho Kinase in Patients With Atherosclerosis

NCT00115830
View directory record Official record
Conditions
Atherosclerosis
Interventions
Atorvastatin, Rosuvastatin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2007 · Synced Oct 15, 2026, 10:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Paroxetine on COAT-Platelet Production in Normal Volunteers and Patients With Cardiovascular Disease

NCT00229528
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Paxil-CR
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 22, 2008 · Synced Oct 15, 2026, 10:59 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Change in Exercise Capacity as Measured by Peak Oxygen Uptake After CTO PCI

NCT02499666
View directory record Official record
Conditions
Coronary Artery Disease, Angina Pectoris
Interventions
Percutaneous Coronary Intervention, Coronary stent, Clopidogrel
Procedure · Device · Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Oct 15, 2026, 10:59 AM EDT
Terminated Phase 3 Interventional

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

NCT00990327
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Apadenoson SPECT-MPI, Adenosine SPECT-MPI
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
103
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Oct 15, 2026, 10:59 AM EDT
Terminated Phase 2 Interventional Results available

Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis

NCT00670202
View directory record Official record
Conditions
Carotid Stenosis
Interventions
Fasudil Hydrochloride, Placebo Oral Tablet
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 15, 2026, 10:59 AM EDT